1 – 10 of 11
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
- Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib
- 2019
- Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
- 2018
- Role of ZNF224 in c-Myc repression and imatinib responsiveness in chronic myeloid leukemia
- A Role for the Non-Receptor Tyrosine Kinase Abl2/Arg in Experimental Neuroinflammation
- 2015
- Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib
- Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
- 2014
-
Risk Factors for Gastrointestinal Stromal Tumor Recurrence in Patients Treated With Adjuvant Imatinib
Joensuu, Heikki ; Eriksson, Mikael LU
; Hall, Kirsten Sundby
; Hartmann, Joerg T.
; Pink, Daniel
; Schuette, Jochen
; Ramadori, Giuliano
; Hohenberger, Peter
; Duyster, Justus
and Al-Batran, Salah-Eddin
, et al.
(2014)
In Cancer
120(15).
p.2325-2333
Mark
- Comparison of MRD monitoring by IG/TR rearrangement and BCR/ABL1 transcript in PH+ pediatric acute lymphoblastic leukemia patients treated with imatinib in the EsPhALL study
- 2012
-
Adjuvant therapy in primary GIST: state-of-the-art
Reichardt, P. ; Blay, J. -Y. ; Boukovinas, I. ; Brodowicz, T. ; Broto, J. M. ; Casali, P. G. ; Decatris, M. ; Eriksson, Mikael LU
; Gelderblom, H.
and Kosmidis, P.
, et al.
(2012)
In Annals of Oncology
23(11).
p.2776-2781
Mark
- 2011
- Efficacy and safety of imatinib on top of BFM-like chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL). the EsPhALL study